Universidad Rey Juan Carlos
Alcorcón, Madrid, 28922, Spain
NCT Number: NCT07247760
The clinical trial aims to evaluate patient satisfaction and the efficacy of home whitening with 10% carbamide peroxide in masking white spot lesions, as well as the presence of sensitivity and gingival irritation.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Alcorcón, Madrid, 28922, Spain
The clinical trial aims to evaluate patient satisfaction and the efficacy of home whitening with 10% carbamide peroxide in masking white spot lesions, as well as the presence of sensitivity and gingival irritation. Patients with at least one white spot due to enamel development defects in any of the anterior teeth will be selected, up to a minimum of 67 lesions. An initial characterisation of the white spot lesions will be performed using different standardised photographs with cross-polarisation filters, fluorescence and transillumination. In addition, mapping will be performed using a spectrophotometer to record the L*a*b* parameters in the lesions and surrounding tissue, and patients will initially respond to a survey on their satisfaction with the lesions (VAS scale) and their impact on psychosocial well-being and oral health-related quality of life (PIDAQ and OHIP-14, respectively). Patients classified for the study will be whitened with 10% carbamide peroxide for 3 hours a day for 4 weeks, or until the desaturation obtained is to their liking, or until the CIELAB L* parameter measurements indicate stabilisation of brightness using the spectrophotometer. During treatment, the presence of sensitivity and irritation will be recorded using a VAS scale. Patients will be reviewed 4 weeks after the end of treatment and will respond again to the questionnaire on satisfaction, psychosocial impact of dental aesthetics and oral quality of life (PIDAQ and OHIP-14), and the lesions will be characterised again. The data obtained on satisfaction, PIDAQ and OHIP-14 surveys will be statistically analysed, as will the colour difference between the lesions and the surrounding tissue enamel at the end of treatment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Whitening treatment with 10% carbamide peroxide on teeth with white spot lesions. Assess patient satisfaction with the masking of white spot lesions and the occurrence of tooth sensitivity and gingival irritation.
Time frame: 2 weeks
The patient will answer questions using the PIDAQ questionnaire to assess whether they consider their white spot lesions to be masked after the whitening treatment.
Time frame: 2 weeks
The lesions will be characterised as described above at 4 weeks and one month after the end of the whitening treatment. If the whitening treatment is prolonged, this will also be done at the end of the treatment. The effectiveness of masking will be determined by the colour difference between the lesions and the surrounding tissue using the CIELAB formula (De L'Eclairage, 1978):
∆Eab = [(∆L*)2 + (∆a*)2 + (∆b*)2]1/2. By definition, a tooth is considered masked when the colour difference (ΔEab) between the lesions and the surrounding healthy enamel is ΔEab ≤3.7, and unmasked if ΔEab > 3.7. A colour difference below the acceptability threshold of 3.7 was chosen as an indicator of masking.
In addition, the colour change will also be calculated using the CIEDE 2000 formula:
Additionally, the CIEDE2000 formula will be applied;
∆E00 = [(ΔL/kLSL)2 + (ΔC/kCSC)2 + (ΔH/kHSH)2 + RT(ΔC*ΔH/SC*SH)]1/2
and the whiteness index (WI)
Time frame: 2 weeks
We will assess sensitivity and intensity using a visual analogue scale (VAS) from 0 to 10. Each patient will be given a diary covering the two weeks between appointments, which they will have to fill in daily. Zero will represent 'no pain' on the visual analogue scale and ten will represent 'severe pain'. Patients will be asked to record the worst result once a day, even if there has been no pain, marking with a vertical line the value corresponding to the intensity of their tooth sensitivity, which will then be measured in centimetres. If the patient marks any value above zero, it will be interpreted as tooth sensitivity. In cases of severe sensitivity, desensitising agents or analgesics/anti-inflammatories will be dispensed.
Time frame: 2 weeks
We will assess gingival irritation and the intensity of said irritation using a visual analogue scale (VAS) from 0 to 10 by means of a diary that will be provided together with the dental sensitivity diary, which the patient will fill in the same way, with zero being 'no gingival irritation' and ten being 'severe irritation'. Patients will be asked to record the worst result once a day, even if there has been no irritation, marking with a vertical line the value corresponding to the intensity of gingival irritation, which will then be measured in cm.
Time frame: 2 weeks
We will assess the appearance of new lesions during treatment using a visual analogue scale (VAS) from 0 to 10 in a diary that will be provided along with the tooth sensitivity diary, which the patient will fill out in the same way, with zero being 'very dissatisfied' and ten being 'very satisfied'. Patients will be asked to record the worst result once a day by marking with a vertical line the value corresponding to the intensity of gingival irritation, which will then be measured in centimetres.
Universidad Rey Juan Carlos
Other
PATIENT SATISFACTION AND MASKING OF WHITE SPOT LESIONS AFTER HOME WHITENING WITH 10% CARBAMIDE PEROXIDE: CLINICAL TRIAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07289932
White Spot Lesions
Cairo, Egypt
View Trial DetailsNCT07715552
White Spot Lesions
Irbid, Jordan
View Trial DetailsNCT07707336
Enamel Demineralization, White Spot Lesions
Ajman, United Arab Emirates
View Trial DetailsNCT06616207
Gingival Diseases, Gingival Inflammation and Bleeding
Seattle, Washington, United States
View Trial Details